Cell-fate control gene therapy (CFCGT)-based strategies can augment existing gene therapy and cell transplantation approaches by providing a safety element in the event of deleterious outcomes. Previously, we described a novel enzyme/prodrug combination for CFCGT. Here, we present results employing novel lentiviral constructs harboring sequences for truncated surface molecules (CD19 or low-affinity nerve growth factor receptor) directly fused to that CFCGT cDNA (TmpkF105Y). This confers an enforced one-to-one correlation between cell marking and eradication functions. In-vitro analysis demonstrated the full functionality of the fusion product. Next, low-dose 3 0 -azido-3 0 -deoxythymidine (AZT) administration to non-obese diabetic/ severe combined immunodeficiency (NOD/SCID) mice injected with transduced clonal K562 cells suppressed tumor growth; furthermore, one integrated vector on average was sufficient to mediate cytotoxicity. Further, in a murine xenogeneic leukemialymphoma model we also demonstrated in-vivo control over transduced Raji cells. Finally, in a proof-of-principle study to examine the utility of this cassette in combination with a therapeutic cDNA, we integrated this novel CFCGT fusion construct into a lentivector designed for treatment of Fabry disease. Transduction with this vector restored enzyme activity in Fabry cells and retained AZT sensitivity. In addition, human Fabry patient CD34 þ cells showed high transduction efficiencies and retained normal colony-generating capacity when compared with the non-transduced controls. These collective results demonstrated that this novel and broadly applicable fusion system may enhance general safety in gene-and cell-based therapies.
INTRODUCTION
Transplantation of hematopoietic stem cells and lymphocytes is a curative treatment for inherited and acquired disorders. However, complications can limit the safety of allogenic and autologous transplantation. One complication is graft-versus-host disease. Likewise, recent serious adverse events regarding the use of genetically modified T cells expressing synthetic chimeric antigen receptors for generating antitumor immunity have also highlighted the need for safer protocols. 1, 2 Cell-fate control gene therapy (CFCGT)-based strategies can be used universally where any cell is transduced with therapeutic vectors or transplanted outside of its normal context. To date, the most widely used CFCGT system is the herpes simplex virus thymidine kinase gene (HSV-TK) that confers ganciclovir (GCV) sensitivity to transduced cells. Phase I --II clinical trials have shown safety and proof-of-principle outcomes with the HSV-TK/GCV system; however, they have also uncovered a number of areas where improvements can be made. 3, 4 First, limited persistence of HSV-TK gene-modified cells due to the immunogenicity of the foreign transgene product has been reported. 5 Second, HSV-TK escape variants have been identified that evade prodrugmediated deletion. 6 --8 Third, the kinetics of GCV activation are suboptimal and overexpression of HSV-TK mostly shifts the ratelimiting step in GCV activation to the next enzyme in the pathway, guanylate kinase. 9 In light of the above limitations, efforts have been made to improve the existing HSV-TK/GCV system, such as by identifying variants with improved enzyme kinetics, or combining it with guanylate kinase overexpression. 10 --12 Recently, another CFCGT system has been implemented in the clinic. 13, 14 There a chemical agent (AP1903) facilitates the activation of a human-modified caspase-9 by mediating dimerization and inducing apoptosis of the engineered T cells. Even though the initial results show the abrogation of early graft-versus-host disease events due to a rapid eradication of modified T cells; however, this CFCGT system requires more study concerning the use of such a dimerizer and long-term clinical implementation.
To overcome major shortcomings of existing cell-fate control systems, we previously described human thymidylate kinase (Tmpk) mutant enzymes combined with the prodrug 3 0 -azido-3 0 -deoxythymidine (AZT) as a novel CFCGT system. 15 A single aminoacid substitution resulted in a minimally modified mutant Tmpk enzyme (TmpkF105Y) with increased catalytic activity for AZT. 16, 17 As described by Sato et al., 15 overexpression of the TmpkF105Y variant mediated by a recombinant lentiviral vector (LV) renders cells extremely sensitive to normally non-toxic AZT, leading to apoptosis via two mechanisms: phosphorylated AZT can be incorporated into DNA during cell replication causing termination of elongated chains, and activated AZT can lead to the loss of mitochondrial membrane potentials and increased cleavage of caspase-3 leading to apoptosis independent of cell-cycle status.
Our previously described cell-fate control gene delivery platform consisted of a bicistronic LV containing the cDNAs of the mutant Tmpk and truncated human CD19 (CD19D) as a cellsurface marker separated by an internal ribosome entry site (IRES). 15 However, that system was hampered somewhat by disjointed expression due to the IRES element between the mutant Tmpk effector enzyme and the cell-surface molecule, which can be used to enrich, track and even eliminate vectorpositive cells. 18 Inclusion of that basal IRES element in the vector backbone also diminished applicability concerning tandem addition of other therapeutic cDNAs.
To obviate the above issue, we have generated novel LV constructs that engineer the expression of directly in-frame fused, truncated cell-surface markers with TmpkF105Y. The first iteration is a truncated human CD19 fused to the mutant Tmpk (LV/CD19DTmpkF105Y), and the second is a fully human, codon-optimized (CO), truncated low-affinity nerve growth factor receptor (LNGFR) fused to the mutant Tmpk (LV/LNGFRDTmpkF105Y). Thus, both LVs confer an enforced one-to-one correlation between the cell marking and eradication functions. We hypothesized that creating such fusion enzymes would still allow Tmpk dimerization, maybe even facilitate it, while this tethering to the cell membrane via the cell-surface marker component may enhance activation of AZT by localizing the enzyme at the cellular entry site of the prodrug.
In the present study, we demonstrated that AZT-mediated cell killing enabled by these novel fusion enzymes is at least as effective as was previously observed for mutant Tmpk alone. In-vitro studies and in-vivo analyses involving two independent models confirmed the broad applicability of these constructs. Further, to demonstrate the contextual utility of this fusion cassette, we also generated a therapeutic LV for the correction of Fabry disease. Fabry disease is a lysosomal storage disorder due to a deficiency in the activity of a-galactosidase A (a-gal A). Indeed, we have previously demonstrated that Fabry disease can be corrected systemically by LV-mediated gene therapy targeting hematopoietic stem cells. 19 However, even with these encouraging results, there are still concerns of insertional mutagenesis with integrating vectors leading to leukemogenesis as exemplified from past X-linked severe combined immunodeficiency (SCID) clinical trials. 20, 21 As such, we demonstrate here vigorous a-gal A expression and AZT-mediated cell killing. Thus, these fusion enzyme systems may serve as robust identification and safety cassettes to supplement existing cell-and gene-based therapies. Figure 1 shows schemas of the recombinant LVs we have constructed for these studies. The first LV, CD19DTmpk, was constructed by fusing the truncated human CD19 cDNA in-frame to the N-terminal residue of human mutant Tmpk (TmpkF105Y). A second cell-fate control fusion cassette was also generated using the cell-surface marker LNGFRD that has already been used in clinical trials. 3 To further enhance the expression of the second construct, the entire human LNGFRDTmpk cassette was fully CO before synthesis; B22% of the sequence was ultimately replaced by optimal codons (data not shown).
RESULTS

Synthesis of novel LVs engineering expression of mutant Tmpk fused to cell-surface molecules
To assess fusion protein expression levels engineered by the novel cell-fate control LVs, K562 cells were infected a single time at a functional multiplicity of infection (MOI) of 10. Under these conditions, the transduced K562 cells were found to be B15% CD19, or B20% LNGFR positive, respectively (data not shown). Transduced cell pools were expanded in culture and enriched for transgene expression by fluorescent-activated cell sorting (FACS). Cells were found to stably express truncated human CD19 or LNGFR, with enriched populations 498% positive compared with the non-transduced (NT) controls (Figure 2a) . A western blot for Tmpk expression was next performed on lysates from the transduced K562 cells (Figure 2b ). All samples, including controls, demonstrated a background band at B24 kDa, which is the expected size for wild-type Tmpk. The K562 cell line overexpressing the mutant Tmpk (non-fusion) was derived previously in our laboratory. 15 These cells showed a marked overexpression of Tmpk compared with the NT controls. As expected, cells expressing the CD19DTmpk or LNGFRDTmpk fusion proteins showed a band of increased molecular weight (B60kDa) confirming that Tmpk is fused to its truncated cell-surface molecules and is stably expressed.
Characterization of clonally-derived populations of transduced K562 cells A robust cell-fate control system should be able to mediate induced killing with relatively low transgene expression levels and with only one integrated vector copy number. Therefore by limiting-dilution cloning of the enriched, transduced K562 cell populations, we established eight cell lines that demonstrated stable expression of variable amounts of truncated human CD19 (Figure 3a) to perform functional quantification studies. On the Figure 1 . Schemas of the novel recombinant lentiviral vectors constructed for these studies. CD19DTmpk, truncated human CD19 fused to mutant human thymidylate kinase (TmpkF105Y); LNGFRDTmpk, truncated CO human LNGFR molecule fused to TmpkF105Y; cPPT, central polypurine tract; EF1-a, elongation factor 1-a promoter; LTR, long terminal repeat; RRE, Rev responsive element; SA, 3 splice acceptor site; SD, 5 splice donor site; SIN, selfinactivating LTR; c, human immunodeficiency virus packaging signal. (Figure 3a ). These differences in the CD19 ABC of clones H5 and L2 are recapitulated in the representative flow cytometry histograms (Figure 3b ). Importantly, there were no observed differences in cell proliferation or viability among the different clones, even when supranormal levels of the fusion transgene were being expressed (data not shown). Quantitative real-time PCR of genomic DNA prepared from the transduced cells showed that both clones H5 and L2 contained B1 copy of the integrated provirus per cell (Figure 3c ).
Sensitivity of clonally derived transduced K562 cells to AZT Next, we tested the sensitivity of the characterized K562 transduced cell clones to the prodrug, AZT. We incubated low and high CD19 expressing K562 clones with increasing concentrations of AZT for 3 days and examined the incidence of apoptosis on day 4 by Annexin V staining. As shown in Figure 4a , both clones undergo apoptosis in a dose-dependent manner when treated with increasing concentrations of AZT. As expected, K562 clones expressing higher levels of mutant Tmpk demonstrated more Annexin V staining, likely due to increased phosphorylation of AZT to its toxic metabolites. At AZT concentrations of 10 mM, clone H5 showed nearly an eightfold increase in the apoptotic index, compared with a fourfold increase for clone L2. In addition, cell viability was measured independently by the MTS assay after exposure to increasing concentrations of AZT (Figure 4b ). The high-expressing clone appeared to be more sensitive to AZT, but of particular interest, the lower expressing clone was ultimately still eradicated to a similar extent, demonstrating the robust sensitivity of this system. Further, both clones selectively demonstrated significant cytotoxicity at concentrations as low as 0.1 mM AZT (Po0.001 compared with NT control). Indeed, transduced cells were minimally viable after exposure to any AZT, and at higher concentrations of the prodrug (41 mM), no cells could be expanded in the longer term (data not shown).
In-vivo killing of low-and high-expressing clonally derived K562 CD19DTmpk-transduced cells in a subcutaneous tumor model We next examined killing of the low-and high-expressing CD19DTmpk-transduced K562 clones in an in-vivo tumor model. In all, 1 Â 10 7 transduced or control cells were injected subcutaneously into the dorsal flanks of non-obese diabetic/severe combined immunodeficiency (NOD/SCID) mice. To minimize variation between animal groups, low-and high-expressing K562 clones (L2 and H5) were injected into the left and right flanks, respectively, of the same animal. Starting 1 day after cell inoculation, the mice received daily injections of AZT at concentrations of 17.1 mg kg À1 per day for a period of 2 weeks.
This drug concentration was calculated based on the FDA recommended dose of 1200 mg per day (17.1 mg kg À1 per day for an average 70 kg individual) for acute treatment of HIV infection in humans. 15, 22 Mice were killed when control tumors reached the maximal allowable size of B1500 mm 3 , which occurred B24 days after cell injection. As shown in Figure 5a , mice that received the NT K562 cells and AZT treatment quickly developed large tumors in a time-dependent manner. Likewise, mice that received the L2 and H5 CD19DTmpk clones without AZT treatment also developed large tumors in the same timedependent manner. In contrast, growth of the low-and highfusion protein expressing tumors in animals receiving AZT was strongly inhibited. At the point of kill, tumors from all mice (if any were present) were extracted and weighed. As shown in Figure 5b , there were striking differences in tumor masses between the AZTtreated and non-treated mice. Both clones showed significant reduction in tumor mass (Po0.005), with no statistical differences (P ¼ 0.197) between them. This emphasizes that minimal transgene expression may also be sufficient to mediate Tmpk/AZT killing in vivo. As well, there was no statistical difference between the tumor masses of NT K562 cells in animals that received AZT, compared with the tumors not treated with AZT (low and high, P ¼ 0.288, P ¼ 0.844, respectively). This shows that there is only specific cytotoxicity against transduced K562 cells and not against parental cells at these clinically-relevant doses of AZT.
Although cell killing was quite robust with AZT, some mice of the experimental group did grow tumors, although of a significantly smaller size than those in the control group. A major concern highlighted from HSV-TK/GCV clinical trials was that some cells evaded drug sensitivity due to the spontaneous mutations in the transgene and loss of effector enzyme expression. 6 Accordingly, we investigated the possibility that some K562 clonal cells had escaped drug sensitivity. To evaluate this, we extracted and examined these tumor cells more extensively in vitro. After the tumors were weighed at the time of euthanasia, they were mechanically and enzymatically processed to allow for expansion of remaining (if any) cells in vitro. Within a few weeks of expansion, these cells were assayed for CD19 expression by flow cytometry and for sensitivity to AZT. As shown in Figures 5c and d, all cells that were expanded remained CD19 positive and were still sensitive to AZT in a dose-dependent manner (Po0.001) at concentrations as low as 1 mM.
Enhanced survival with AZT addition of NOD/SCID mice harboring LV/LNGFRDTmpk-transduced human leukemic cells We next asked whether LV/LNGFRDTmpk transduction could enhance survival of AZT-treated NOD/SCID mice in a murine xenogeneic tumor model of lymphoid leukemia. For this, Raji cells (human Burkitt's lymphoma B-cell line) were transduced and enriched by FACS (Figure 6a ). In-vitro cytotoxicity assays showed Engineered human Tmpk-cell-surface marker fusions M Scaife et al that the pool of transduced Raji cells were selectively sensitive to AZT in a drug dose-dependent manner with significant viability loss at concentrations as low as 0.1 mM AZT (Po0.001 compared with NT control) (Figure 6b ). NOD/SCID mice were then inoculated with the transduced polyclonal (LV/LNGFRDTmpk) or NT Raji cells (Figure 6c ). Starting 4 days after inoculation, mice received twice-daily injections for 2 weeks of AZT (17.1 mg kg À1 per injection) or the phosphatebuffered saline (PBS) carrier. For the control groups, tumorigenic activity, as evidenced by total hind-limb paralysis (with subsequent euthanasia) in all mice, manifested at 18 --25 days post inoculation with a median survival time of B20 days. Concerning the experimental group, mice that received transduced Raji cells with AZT treatment showed a significant increase in survival (Po0.001) compared with the PBS treatment group, with median survival of 26 days (Figure 6c) .
At the time of paralysis/euthanization, peripheral blood and bone marrow (BM) were harvested and analyzed for the presence of the Raji cells. Peripheral blood showed little or no Raji cells in circulation (o1%) (data not shown). As expected, BM obtained from the control groups showed a high prevalence of transduced (human CD19 þ LNGFR þ ) or NT (human CD19 þ ) Raji cells of 23.5% for both groups ranging from 8.0 to 80.0% and 5.5 to 40.9%, respectively. In contrast, healthy mice euthanized from the experimental group (LNGFRDTmpk þ AZT) within this same timeframe (19 --21 days post inoculation) only showed a median engraftment of leukemic cells of 6.6% (ranging from 0.2 to 9.2%; Figure 6d ). Remarkably, one mouse in the experimental group showed only 0.2% CD19-positive cells in the BM, suggesting that the AZT at this dose had effectively eradicated the transduced cells in that case.
Specific enrichment and AZT-mediated killing of LV/ LNGFRDTmpk-transduced primary human T cells To investigate the efficacy of our novel LNGFRDTmpk safety cassette for prevention of potential serious adverse events (that is, graft-versus-host disease) associated with T-cell immunotherapies, we transduced and expanded primary human T cells from peripheral blood collected from a healthy donor, using a protocol analogous to current clinical preparation of primary human T cells for adoptive immunotherapy or chimeric antigen receptor immunotherapy. Expanded T cells were transduced with LV/LNGFRDTmpk at an MOI of 100. The transduction process did not affect the frequency of CD3 expression, and B44% of T cells expressed LNGFR after a single transduction (Figures 7a and b) . Therapeutic LV targeting Fabry disease generates both enzyme correction in transduced cells and sensitivity to AZT In 'proof-of-principle' studies, a novel LV designed for amelioration of Fabry disease was also endowed with the CFCGT safety cassette. To evaluate if the LV/LNGFRDTmpk-IRES-COa-gal A we engineered could provide enzymatic correction, a human Fabry B-cell line was transduced a single time at an MOI of 100. Cells were found to be B15% positive for LNGFRD or B70% positive for control enGFP expression (data not shown). Transduced Fabry B cells were enriched by FACS and found to be 498% positive for LNGFR expression (Figure 8a ). When the a-gal A enzyme activity was assayed on lysates from the enriched cells, we found that human Fabry B cells showed fully restored enzyme activity compared with NT or LNGFRDTmpk Fabry B cells (Po0.001); in fact a nearly twofold activity increase over that seen in normal B cells (Figure 8b ). In addition, in-vitro cytotoxicity assays showed that the transduced polyclonal Fabry B cells were selectively sensitive to AZT in a similar dose-dependent manner as seen above with significant cytotoxicity observed at concentrations as low as 0.1 mM AZT (Po0.001 compared with NT control; Figure 8c ). To demonstrate clinical applicability of this novel therapeutic/ safety vector for therapeutic amelioration of Fabry disease, we transduced human CD34 þ cells enriched from peripheral blood Here, we have expanded on our previous human Tmpk/AZT system, 15 which already overcame many of the limitations of existing suicide genes, such as immunogenicity of the transgene, poor enzyme kinetics and unfavorable prodrug utilization. To enhance applicability and portability, we have created two novel fusion Tmpk variant enzymes utilizing truncated human cell-surface markers, CD19 and LNGFR. Both fusion constructs were stably expressed and retained their Tmpk/AZT-mediated killing functionalities. Importantly, the fused cell-surface markers and kinases are now expressed at an enforced one-to-one level. Use of such cell-surface molecules will not only allow for enrichment and tracking but also will enable a secondary cell killing approach. 18 For instance, phase I clinical studies have been conducted using a CD19-directed antibody conjugated to the Ricin A toxin. 23, 24 Along these lines, combination therapies of CD19-immunotoxin and AZT may show even greater eradication of transduced cells.
We demonstrated that these novel cell-fate control safety cassettes we generated can be used to control the survival of transduced cells both in vitro and in vivo. Indeed, our xenograft-NOD/SCID tumor model showed significant suppression of tumor growth (Figures 5a and b) . Of particular importance, we further showed that only 1 vector copy per cell with relatively low transgene expression was sufficient to mediate Tmpk/AZT killing. Worth noting as well is that clones H5 and L2 show a different Engineered human Tmpk-cell-surface marker fusions M Scaife et al level of transgene expression in spite of the similar copy number ( Figure 3) ; this is probably due to different integration sites or epigenetic status of the surrounding chromatin. One previous shortcoming of the older-generation HSV-TK/GCV system was that the HSV-TK cDNA contained active cryptic splice sites, resulting in a fraction of up to 5% of transduced target cells insensitive to drug-mediated killing. 6 Here, we confirmed that the remaining tumor cells were not escape mutants or evading drug selection, as remaining residual tumor cells were sensitive to AZT in vitro (Figures 5c and d) . This suggests that the drug treatment regimen in this case may not have been aggressive enough to completely eradicate all of the infused tumor cells. However, this result is Engineered human Tmpk-cell-surface marker fusions M Scaife et al quite notable considering the low drug dose of 17.1 mg kg À1 per day that was used, compared with data from mice treated with AZT at 270 mg kg À1 per day for 15 days, which only exhibited marginal toxicity. 25 In our other in-vivo model, we found a significant increase in the survival of animals harboring the transduced polyclonal Raji cells following 2 weeks of AZT treatment (Figure 6c ). Yet, AZT treatment did not fully prevent animals from succumbing to the disorder. The aggressiveness of this leukemia-lymphoma model and a less than-optimal drug-dosing regimen may have contributed to this. In the clinic, to prevent fetal transmission of HIV, HIV þ pregnant women are treated orally with 100 mg of drug, five times per day. At labor time, the treatment is reinforced with 2 mg kg À1 during the first hour followed by continuous infusion of 1 mg kg À1 per hour until clamping of the umbilical cord. The reason behind this aggressive and continuous dosing of AZT is due to its short plasma half-life, which is as low as 30 min. 22 Although the short half-life or desirable frequency of administration of AZT to mice was a challenge in these aggressive disease studies, this would likely not to be problematic in humans given that AZT is already commonly used in the clinic either as a continuous i.v. infusion or is given in multiple oral doses. Along these lines, we believe that enhancing the AZT half-life through drug modification may further improve our cell-fate control system. This work is already under investigation for enhancing the efficacy of this drug for treatment of HIV. 26 --28 Another major consideration is the biodistribution of the prodrug versus accessibility of privileged sites in the animal. The cells used in these leukemia-lymphoma models have been selected over generations to be very aggressive. They also migrate to the regions that are less accessible to the drug, such as the spinal cord and brain. 29, 30 These models may thus be too stringent to study a realistic onset of leukemia in a gene therapy context.
Our laboratory is currently transitioning to using these safety cassettes in gene therapy approaches for inherited disorders. One of our present applications of these cell-fate control safety cassettes is to safeguard against insertional oncogenesis in LV-mediated therapy for Fabry disease. To this end, a novel LV that engineers the expression of LNGFRDTmpk along with an intact human COa-gal A cDNA was constructed in this present study.
Transduction of human Fabry B cells and human CD34
þ cells with this LV resulted in supranormal levels of a-gal A expression and activity (Figures 8b and 9c ). Having these supranormal levels of a-gal A is desirable to facilitate metabolic cooperativity or crosscorrection. Of particular importance, strong overexpression of a-gal A is well tolerated, as transgenic mice with a-gal A levels up to 11 080-fold higher than normal displayed no associated toxicity. 31 These data suggest that a-gal A downstream of an IRES element may be sufficient to provide enzymatic correction in Fabry disease, in part owing to the premise that as little as 5 --10% of residual enzyme activity seems to be sufficient to prevent clinical accumulation of glycosphingolipids. 32 Our laboratory is currently in preclinical validation of this LV for the treatment of Fabry disease. Although future work is currently ongoing to evaluate this therapeutic vector for treatment of Fabry disease, these present results themselves are encouraging. Even with very limited Fabry patient CD34 þ cells, we showed high expression levels of LNGFR cell-surface marker on transduced cells, and transduced cells retained normal colony-generating capacity when compared with the NT controls. Furthermore, we demonstrated high levels of secreted a-gal A in LV/LNGFRDTmpk-IRESCOa-gal A-transduced CD34 þ cells. Treatment of Fabry disease is only one of the many possible applications of this system. We have also demonstrated effective selection and AZT-mediated killing in human primary T cells using the LNGFRDTmpk element following a clinically analogous expansion and selection protocol. These safety cassettes are already incorporated into some of our adoptive immunotherapy constructs and we have recently demonstrated the successful use of the CD19DTmpk cassette for cell eradication in an adoptive immunotherapy approach using T cells engineered to also express PDL1. 33 These results highlight the clinical feasibility of these fusion cassettes in both therapeutic gene therapy and cell-based immunotherapy scenarios.
MATERIALS AND METHODS Materials
Roswell Park Memorial Institute (RPMI-1640), Dulbecco's Modified Eagle's Medium, AZT and collagenase II were from Sigma (Oakville, ON, USA). Fetal bovine serum was from PAA (Toronto, ON, Canada). Glutamine, penicillin and streptomycin were from Invitrogen (Carlsbad, CA, USA). KOD Hot Start DNA Polymerase was from Toyobo (Osaka, Japan). The TA cloning vector pGEM-T Easy was from Promega (Madison, WI, USA). Antibodies used for flow cytometry were PE-conjugated anti-human CD19 monoclonal antibody (anti-CD19-PE), anti-CD19-APC and CD271-PE (all from BD Biosciences, San Jose, CA, USA).
Construction of the CD19DTmpk fusion LV
The cDNA for both CD19D and TmpkF105Y was amplified from a previously constructed shuttle vector pSV-TmpkF105Y-IRES-CD19D 15 and ligated into the TA cloning vector pGEM-T. To generate the CD19DTmpkF105Y fusion cassette and to facilitate the proper folding of the both proteins, a six amino-acid linker peptide (Ala-Gly-Gly-Ala-Ala-Gly) was inserted between both construct components. The CD19DTmpkF105Y cDNA sequence was then excised and subcloned into the self-inactivating (SIN) HIV-based lentiviral backbone (pDY'cPPT-EF1a-woodchuck hepatitis virus post-transcriptional regulatory element (WPRE)) previously generated in our laboratory from the pHR'.cPPT.EF-1a.EGFP.WPRE.SIN. 19 Briefly, in an effort to reduce the size of the transfer vector and to facilitate future subcloning procedures, non-essential elements of the original transfer vector backbone and long terminal repeat sequences were deleted via PCR mutagenesis. The PCR-amplified fragment was subsequently subcloned into the pGEM vector and the newly engineered transfer vector was then denoted as pDY.cPPT.EF-1a.EGFP.WPRE.SIN. The fidelity of the final construct was confirmed by restriction enzyme digests and bidirectional DNA sequencing.
Construction of the LNGFRDTmpk fusion LV
A CO cDNA sequence of human LNGFRDTmpk was synthesized by GenScript (Piscataway, NJ, USA). The human LNGFR cDNA sequence was truncated in the intracellular domain. The entire CO LNGFRDTmpkF105Y sequence was synthesized with a 5 0 flanking AscI site and a Kozak consensus sequence along with a 3 0 BamHI site. The COLNGFRDTmpkF105Y sequence was then subcloned into the SIN HIV-based lentiviral backbone (pDY' EF1a-WPRE). The fidelity of the final construct was confirmed by restriction enzyme digests and bidirectional DNA sequencing.
Construction of the LNGFRDTmpk-IRES-COagalA LV
A CO cDNA sequence of human a-gal A gene was synthesized by DNA2.0 (Menlo Park, CA, USA). The COa-gal A cDNA was amplified by PCR and subcloned into a TA cloning vector, excised and used to replace the eGFP element from a pDIG-CMV-DsRed-IRES-eGFP vector previously constructed in our laboratory (unpublished results). Then, the IRES-COa-gal A component was amplified, digested and ligated into the BamHI site downstream of the LNGFRDTmpk element of the pDY-LNGFRDTmpk plasmid. The fidelity of the final construct was confirmed as above.
Cell culture HEK 293T cells (human embryonic kidney cells) were cultured in Dulbecco's Modified Eagle's Media while K562 cells (human erythroid leukemia cells), Raji cells (Burkitt's human lymphoma B cells) and a Fabry patient-derived B-cell line 34 were cultured in RPMI-1640 media. Both media were supplemented with 10% fetal bovine serum, 2 mM glutamine, Engineered human Tmpk-cell-surface marker fusions M Scaife et al À1 penicillin and 100 mg ml À1 streptomycin. All cells were maintained in a humidified incubator at 37 1C with 5% CO 2 .
Fabry Culture and enrichment of primary T lymphocytes Human primary T lymphocytes were expanded from Ficoll-paque PLUS isolation of peripheral blood mononuclear cell cultured at 1 Â 10 6 cells per ml in X-Vivo 20 (Lonza, Walkersville, MD, USA) supplemented with 5% inactivated human AB serum (Invitrogen). The T cells were activated using anti-CD3/CD28 beads (three beads per cell) and 20 IU ml Preparation of high-titer LV and functional titer analyses Vesicular stomatitis virus glycoprotein-pseudotyped LVs including control LV/enGFP 15 were generated by transient co-transfection of 293T cells with a three-plasmid system (the transfer construct, the packaging plasmid pCMVDR8.91 and the vesicular stomatitis virus glycoprotein envelope encoding plasmid pMD.G) using PEI transfection (Sigma). Viral supernatants were harvested at 48 and 72 h after transfection, passed through a 0.45-mM filter (Nalgene, Rochester, NY, USA), and ultracentrifuged at 50 000 g for 120 min at 4 1C. The concentrated viral pellets were resuspended in 2% bovine serum albumin in 1 Â PBS and stored in aliquots at À80 1C. Functional viral titers were determined by serial diluting the concentrated LV and transducing naive 293T cells. Transgene expression in such transduced cells was assessed 72 h after infection by flow cytometry. An FACS Calibur flow cytometer (BD Biosciences) and CellQuest software (BD Biosciences) were used for all cell analyses.
Transduction and clonally derived cell lines
Cell lines were infected with concentrated LV stocks for 16 h in the presence of 8 mg ml À1 protamine sulfate. Transgene expression was assessed 72 h after transduction. Transduced cells were also enriched by FACS. For these studies, transduced cells were stained as above and sorted using an MoFlo high-performance flow cytometer (Dako Canada Inc., Burlington, ON, Canada). To obtain clonally derived cell lines, sorted K562 cells were plated in Nyco plates at densities of 0.3 cells per well. Only wells containing a single cell were expanded.
Quantification of CD19DTmpk expression
Quantification of CD19 cell-surface molecule expression on K562 single cell-derived clones was performed using an ABC flow cytometry quantification kit as per the manufacturers instructions (Quantum Simply Cellular, Bangs Laboratory Inc., Fishers, IN, USA). The Quantum Simply Cellular beads and K562 clones were labeled with the anti-CD19-PE monoclonal antibody. By plotting each microsphere population's fluorescence intensity versus its assigned ABC value, a standard ABC curve was generated. A QuickCal analysis Microsoft Excel template (Bangs Labs, Fishers, IN, USA) was used to determine the CD19 ABC of the K562 clones based on the ABC/MFI (mean fluorescence intensity) of the standard beads.
Analysis of transgene expression by western blot
In all, 20 mg of total cell lysates was resolved by 12% SDS-PAGE and transferred onto a PVDF membrane (Millipore, Billerica, MA, USA). Membranes were blocked overnight at 4 1C using 5% w/v non-fat dry milk in PBS-T (0.1% Tween-20 v/v in PBS). A 1:5000 dilution of serum from a rabbit immunized against human Tmpk in 5% non-fat dry milk was applied to the membrane and incubated at room temperature for 3 h. 15 After washing in PBS-T, a secondary goat anti-rabbit IgG antibody conjugated to horseradish peroxidase (Santa Cruz Biotechnology, Santa Cruz, CA, USA), diluted 1:10 000 in 5% non-fat dry milk was added. Proteins were visualized using Western Lightning Chemiluminescence Reagent Plus (Perkin-Elmer, Woodbridge, ON, USA). Protein loading amounts were confirmed with a monoclonal anti-b-actin primary antibody (Chemicon International, Billerica, MA, USA).
Vector copy number assessed by quantitative real-time PCR Genomic DNA was isolated from transduced K562 clones using the Gentra Puregene Blood kit (Qiagen, Valencia, CA, USA), as per the manufacturer's instructions. Quantitative real-time PCR for the WPRE element in the LV and b-actin control was performed for integrated provirus as before 35 using the Corbett Research Rotor Gene RG3000 thermocycler (Concorde, NSW, Australia). A no-template negative control was included; moreover, each reaction was performed in triplicate, and mean Cycle Threshold values were calculated. A standard curve to determine vector copy number was created using serial dilutions of genomic DNA from a 293T-based cell line we previously generated that contains one integrated provirus. 35 Determination of sensitivity of transduced cells to AZT Cells were seeded at a density of 5 --10 Â 10 6 cells per ml and treated daily with increasing concentrations of AZT for 4 consecutive days. On day 7, cell viability was determined using the Cell Titer 96 Aqueous One Solution Cell Proliferation Assay kit (Promega) as per the manufacturer's specifications. Cell viability was calculated by normalizing absorbance values at each concentration of AZT against its respective non-treated value for each group. Standard deviation is representative of normalized absorbance values performed in quadruplicates, and statistical significance between groups was calculated by the two-tailed, Student's t-test.
For evaluation of the induction of apoptosis, cells were treated with different AZT concentrations during 3 days. On day 4, the cells were stained with FITC Annexin V (BD Biosciences) and propidium iodide and flow cytometry was performed. Data obtained were normalized by dividing results from the AZT-treated cells in each group by the results obtained without AZT treatment.
Subcutaneous tumor model of K562 cells in NOD/SCID mice All animal experimental procedures followed a protocol approved by the Animal Care Committee of the University Health Network (Toronto, ON, Canada). NOD/SCID mice (females, 6 --10-week old) were bred in a pathogen-free environment and were maintained at the Animal Resource Centre at the Princess Margaret Hospital (Toronto, ON, Canada). All mice received 1 Â 
